FUND+ PEOPLE INVESTMENT STRATEGY PORTFOLIO YOUR PROJECT NEWS CONTACT US PRIVACY POLICY Disclaimer This website is owned by Fundplus, with its registered office and contact details: Groot Begijnhof 60, 3000 Leuven (Belgium) Tel: +32 (0)16/90.50.00 Fax: +32 (0)16/79.50.25 info@fundplus.be Other parties ‘User’ or ‘you’: any natural person (B2C) or legal person (B2B) who is or will be placed in a contractual relationship of any kind with Fundplus via its online platform. ‘Law’: art. 129 Law on electronic communications, as amended by W 2012-07-10 / 04, art. 90, 017; (entry into force: 04-08-2012)(URL). By accessing and using the website you explicitly agree with the following disclaimer, privacy and cookie policy Intellectual property rights The contents of this site, including the brands, logos, drawings, data, product or company names, texts, images etc. are protected by intellectual rights and belong to Fundplus or entitled third parties. Limitation of liability The information on the website is of a general nature. The information is not adapted to personal or specific circumstances, and can therefore not be considered as personal, professional or legal advice to the user. Fundplus makes every effort to ensure that the information provided is complete, accurate, accurate and up-to-date. Despite these efforts, inaccuracies may occur in the information provided. If the information provided contains inaccuracies or if certain information on or via the website is unavailable, Fundplus will make every effort to rectify this as soon as possible. Fundplus can not be held liable for direct or indirect damage resulting from the use of the information on this site. If you find inaccuracies in the information made available via the website, you can contact the site manager. The content of the site (including links) can be adapted, modified or supplemented at any time without notice or notification. Fundplus gives no guarantees for the proper functioning of the website and can in no way be held liable for a malfunction or temporary (un) availability of the website or for any kind of damage, direct or indirect, that would result from the access to or use of the website. Under no circumstances can Fundplus be held liable in any way whatsoever, directly or indirectly, in any way or any other way, for damage resulting from the use of this site or of another, Applicable law and competent courts. Belgian law applies to this site. In case of a dispute only the courts of the district of Leuven are competent. Privacy policy Fundplus attaches importance to the protection of your privacy and personal data. Although most of the information on this site is available without personal details being provided, it is possible that the user is asked for personal information. This information will only be used in the context of our customer management. The user can, free of charge and on request, oppose the use of his data for direct marketing. To this end, he will address Fundplus,Groot Begijnhof 60, 3000 Leuven – Belgium. Your personal data will never be passed on to third parties (if you do mention the case to whom). Consultation and correction In accordance with the law on the processing of personal data of 08/12/1992, the user has the legal right to inspect and correct his personal data. Subject to proof of identity (copy of identity card), you can receive the written notification of your personal data via a written, dated and signed request to Fundplus, Groot Begijnhof 60, 3000 Leuven – Belgium. If necessary, you can also ask to correct the data that would be incorrect, incomplete or non-pertinent. Cookies Fundplus may collect anonymous or aggregated data of a non-personal nature, such as browser type or IP address, the operating system you use or the domain name of the website from which you came to our website, or through which you leave it. This allows us to permanently optimize our website for the users. What are cookies and why are they important? Cookies are small text files that store websites on your computer or mobile device. They collect information about – for example – your personal preferences, website visit and device in order to improve the functionality and user experience of those websites. Some cookies collect personal data directly or indirectly and are therefore privacy-sensitive. That is why they are also covered by European and Belgian legislation. The use of cookies is regulated by the European Parliament and the Council of the European Union via e-Privacy richtlijn 2002/58/EC. All EU Member States have now transposed that directive into national legislation. This implies that cookie use and cookie legislation will be regulated differently in every European country. In Belgium, this is done via an adapted version of Art. 129 of the Act of 13 June 2005 on electronic communications. Which cookies does Fundplus use and for what purposes? Three different types of cookies are used on the Fundplus website: Essential cookies are cookies that are necessary for a website to function (better), for example cookies that manage the loading time of web pages or that check whether javascript can be used. Functional cookies collect information about the choices and preferences of visitors and offer the possibility to remember and personalize language and other local settings. Analytical or performance cookies collect information about the behavior of visitors to measure the performance of the website in question and to improve the user experience. How can I manage my cookies? You can always manage cookies yourself in your browser settings. Below are instructions for: Mozilla Firefox Windows Internet Explorer Google Chrome Safari Questions or remarks? If you still have questions or comments after reading these guidelines, you can always contact Fundplus via http://fundplus.be/contact. Contact us Address: Groot Begijnhof 60 3000 Leuven Belgium Phone: +32 (0)16 90 50 00 Email: info@fundplus.be Recent Articles ONA Therapeutics Appoints Dr Michel Detheux as Independent Chair to Board of Directors Confo Therapeutics Enters Collaborative Agreement with Regeneron Immunic, Inc. Announces Enrollment of First Patient in its Phase 3 ENSURE Program of vidofludimus calcium (IMU-838) in Relapsing Multiple Sclerosis © 2019 FUND+- ALL RIGHTS RESERVED. | We'll assume you're ok with this, but you can opt-out if you wish. Cookie settingsACCEPTRead More